Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.43 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | TET2 | Q6N021 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TET3 | O43151 | 1/20 | 0.34 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL29766120 | 1.00 | HDAC3 (0.43) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| Trimethylammonium SCHEMBL964726 | 0.98 | HDAC3 (0.42) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| Trimethylammonium SCHEMBL1424158 | 0.98 | HDAC3 (0.42) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| Trimethylammonium SCHEMBL154411 | 0.98 | HDAC3 (0.42) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| Trimethylammonium SCHEMBL136533 | 0.98 | HDAC3 (0.42) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| Methacrylic Acid SCHEMBL17003924 | 0.93 | FFAR3 (0.39) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| SCHEMBL17818 | 0.92 | — | — | |
| Trimethylammonium SCHEMBL5988078 | 0.91 | FFAR3 (0.37) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| Trimethylammonium SCHEMBL524378 | 0.91 | FFAR3 (0.37) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| Sulfuric Acid SCHEMBL8399982 | 0.91 | FFAR3 (0.37) | HDAC3HDAC1HDAC2HDAC8FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104388-A1 | DECONGESTANT CONTROLLED RELEASE DRUG DELIVERY SYSTEM | FAES FARMA, S.A. (ES) | 2026-05-21 | — | — | WO | claimed |
| CN-120118250-A | Surfactant, preparation method and application thereof | 浙江蓝天环保高科技股份有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-120118223-A | Method for adjusting particle size of fluorine-containing polymer emulsion | 浙江蓝天环保高科技股份有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-119970649-A | Amorphous kinase inhibitor formulations and methods of use thereof | 德西费拉制药有限责任公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119950433-A | Amorphous kinase inhibitor formulations and methods of use thereof | 德西费拉制药有限责任公司 | 2025-05-09 | — | — | CN | claimed |
| CN-119528480-A | Concrete early strength agent and preparation method and application thereof | 科之杰新材料集团有限公司 | 2025-02-28 | — | — | CN | claimed |
| US-12163001-B2 | Ion exchange membrane through UV initiation polymerization | EVOQUA WATER TECHNOLOGIES LLC (US) | 2024-12-10 | — | — | US | claimed |
| CN-118063351-B | Green synthesis of chiral beta amino acids using biological enzymes and immobilized aminotransferase used | 北京元延医药科技股份有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-117715632-A | Compositions comprising an enzyme-cleavable prodrug and nafamostat and methods of use thereof | 恩赛斯生物科学股份有限公司 | 2024-03-15 | — | — | CN | claimed |
| US-11648184-B2 | Dental composition containing ion sustained-release glass | SHOFU INC. (JP) | 2023-05-16 | — | — | US | claimed |
| EP-0514814-B1 | Diltiazem formulation | HOECHST MARION ROUSSEL INC (US) | 1997-01-22 | — | — | EP | claimed |
| EP-0706399-A1 | COMPOSITIONS AND PROCESS FOR REMOVING BILE SALTS | GELTEX PHARMACEUTICALS, INC. (US) | 1996-04-17 | — | — | EP | claimed |
| WO-1995034588-A1 | CROSS-LINKED POLYMERS FOR REMOVING BILE SALTS FROM A PATIENT | GELTEX PHARMACEUTICALS, INC. (US) | 1995-12-21 | — | — | WO | claimed |
| US-5470584-A | Sustained release | CARDERM CAPITAL L.P. (CH) | 1995-11-28 | — | — | US | claimed |
| US-5439689-A | Treating cardiovascular disorders by orally administering once-a-day formulation having rapid and delayed release components | CARDERM CAPITAL L.P. (CH) | 1995-08-08 | — | — | US | claimed |
| EP-0662321-A1 | Method for producing osmosis-controlled tablets avoiding the use of chlorinated hydrocarbons | EGIS GYOGYSZERGYAR RT. (HU) | 1995-07-12 | — | — | EP | claimed |
| WO-1994027620-A1 | COMPOSITIONS AND PROCESS FOR REMOVING BILE SALTS | GELTEX PHARMACEUTICALS, INC. (US) | 1994-12-08 | — | — | WO | claimed |
| US-5286497-A | Time-release for one-a-day administration | CARDERM CAPITAL L.P. (CH) | 1994-02-15 | — | — | US | claimed |
| EP-0514814-A1 | Diltiazem formulation | HOECHST MARION ROUSSEL, INC. (US) | 1992-11-25 | — | — | EP | claimed |
| CN-1045524-A | The coating material that is used for the control drug release of durative action preparation | YAMANOUCHI PHARMA CO LTD (JP) | 1990-09-26 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648184-B2 | Dental composition containing ion sustained-release glass | SLCO2B1, CA2, SLCO2A1 | HDAC3 2787/4885HDAC1 2642/4885HDAC2 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.